| 2016-11-23 07:20:57|
AXON, LLY 07:20 11/23 11/23/16
Axovant Sciences drops 18% after Lilly Alzheimer's study failure
Axovant (AXON) is developing its own drug for the treatment of patients with Alzheimer's disease. As previously reported, Eli Lilly (LLY) announced earlier that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease.